Dr V. SRIMUNINNIMIT(1), Dr T. VEERAPREEYAKOL(2) L. THOMASSIN(3) (1) Division of Plastic surgery, Ramathibodi Hospital Faculty of Medecine, Mahidol University, Bangkok, Thailand (2) Division of General surgery, Khon Kaen Hospital, Khon Kaen, Thailand (3) Laboratoires Urgo, Chenôve, France.

1. EXPERIENCE OF THE TLC-NOSF DRESSING*
IN THE MANAGEMENT OF DIABETIC FOOT
ULCERS
Dr V. SRIMUNINNIMIT(1), Dr T. VEERAPREEYAKOL(2)
L. THOMASSIN(3)
(1) Division of Plastic surgery, Ramathibodi Hospital Faculty of Medecine, Mahidol University, Bangkok, Thailand
(2) Division of General surgery, Khon Kaen Hospital, Khon Kaen, Thailand
(3) Laboratoires Urgo, Chenôve, France.
*Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart®
Contact

2. INTRODUCTION
Diabetic foot ulcers are prone to delayed healing (stagnation/aggravation) due to
abnormally high local proteolytic activity (excess liberation of matrix metalloproteinases, or
MMPs).
The NOSF (Nano-Oligo Saccharide Factor) is an innovative compound which has
demonstrated MMP-inhibiting properties.
The authors report the initial results of their clinical tests using a lipido-colloid dressing
impregnated with NOSF* in the local treatment of foot ulcers in diabetic patients,
associated with off-loading of the affected foot.
In these clinical cases, the new compound (NOSF) offers the possibility to equilibrate the
wound micro environment and relaunch the healing process until healing is complete
(case 1) or almost complete (case 2).
*Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart®
Contact

3. Figure 3
76 years-old-female patient, with Type 2
Diabetes Mellitus and ABPI<0,6.
The wound had been stagnant for more than 4
months, and the tendon visible at the wound
bed. It was previously treated with AG
dressings, Zinc Hyaluronate and PDGF gel.
Upon admission, the wound surface area
measured 0,5 x 1 cm² with a depth of
1,0 x 0,7 x 0,4 x 0,5 cm² (fig.1).
After an angioplasty and 8 weeks treatment
with TLC-NOSF dressing*, the wound surface
area is 0,3 x 0,2 cm². The cavity size was
significantly reduced in both circumference and
depth with 90% reepithelialisation (fig.2).
After 12 weeks treatment, complete healing
was observed (fig.3).
Figure 2
Figure 1
CLINICAL CASE STUDY 1
*Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart®
Contact

4. 56 years-old female patient, with Type 2
Diabetes Mellitus and lower member
arteritis.
The 5th toe was amputated and healing
delayed for approximately 3 months.
At inclusion, the wound surface area was
3 x 3,5 cm² (fig.4).
After 1 week of treatment with TLC-NOSF
dressing*, the wound presented with signs of
localized infection, and the decision was
made to switch to a silver dressing for a
period of 2 weeks.
Once the infection had gone, treatment was
continued with the TLC-NOSF dressing* and
after 5 weeks the wound surface area had
significantly decreased, with a measurement
of 0,8 x 0,4 cm² (fig.5).
Figure 4
Figure 5
CLINICAL CASE STUDY 2
*Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart®
Contact

5. These clinical cases illustrate the efficacy, and high level of tolerance and conformability
of the TLC-NOSF dressings* in the local treatment of diabetic foot ulcers associated with
off-loading of the affected foot.
CONCLUSION
*Brand names: the TLC-NOSF dressings are UrgoStart® and UrgoStart®
Contact